Dynamic Technology Lab Private Ltd lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 40.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,400 shares of the biotechnology company’s stock after selling 1,651 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in BioMarin Pharmaceutical were worth $223,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Korea Investment CORP boosted its position in shares of BioMarin Pharmaceutical by 143.5% in the second quarter. Korea Investment CORP now owns 1,595 shares of the biotechnology company’s stock worth $145,000 after buying an additional 940 shares during the period. Global X Management Co. LLC boosted its position in BioMarin Pharmaceutical by 16.8% during the second quarter. Global X Management Co. LLC now owns 1,935 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 279 shares during the last quarter. Toronto Dominion Bank boosted its position in BioMarin Pharmaceutical by 12.9% during the second quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 243 shares during the last quarter. Commerce Bank acquired a new stake in BioMarin Pharmaceutical during the third quarter valued at $209,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in BioMarin Pharmaceutical during the second quarter valued at $213,000. 99.26% of the stock is owned by institutional investors and hedge funds.
In related news, insider Henry J. Fuchs sold 15,000 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the sale, the insider now directly owns 141,422 shares of the company’s stock, valued at $12,798,691. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP George Eric Davis sold 1,200 shares of BioMarin Pharmaceutical stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $85.64, for a total value of $102,768.00. The disclosure for this sale can be found here. Insiders sold 41,886 shares of company stock worth $3,839,086 over the last quarter. 1.85% of the stock is currently owned by corporate insiders.
A number of analysts recently issued reports on BMRN shares. Zacks Investment Research cut BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Piper Jaffray Companies started coverage on BioMarin Pharmaceutical in a research report on Thursday, September 14th. They set an “overweight” rating and a $113.00 price objective for the company. Citigroup started coverage on BioMarin Pharmaceutical in a research report on Thursday, August 31st. They set a “buy” rating and a $98.00 price objective for the company. Royal Bank Of Canada started coverage on BioMarin Pharmaceutical in a research report on Thursday, September 14th. They set a “sector perform” rating and a $93.00 price objective for the company. Finally, Morgan Stanley reissued an “overweight” rating and set a $117.00 price objective (up previously from $115.00) on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $111.59.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at $80.82 on Thursday. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical Inc. has a 12 month low of $79.50 and a 12 month high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $334.18 million for the quarter, compared to analyst estimates of $347.38 million. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The firm’s revenue for the quarter was up 19.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.02 earnings per share. sell-side analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.65 EPS for the current year.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.